PL2886545T3 - Nowe pochodne tienopirymidyn, sposób ich wytwarzania, oraz zawierające je kompozycje farmaceutyczne - Google Patents

Nowe pochodne tienopirymidyn, sposób ich wytwarzania, oraz zawierające je kompozycje farmaceutyczne

Info

Publication number: PL2886545T3
Authority: PL; Poland
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; thienopyrimidine derivatives; new thienopyrimidine
Prior art date: 2013-12-23

Application number

PL14199533T

Other languages

English (en)

Inventor

Andras Kotschy

Zoltán Szlávik

Márton Csékei

Attila Paczal

Zoltán Szabó

Szabolcs Sipos

Gábor Radics

Ágnes Proszenyák

Balázs Bálint

Alain Bruno

Olivier Geneste

James Edward Paul Davidson

James Brooke Murray

I-Jen Chen

Françoise Perron-Sierra

Original Assignee

Les Laboratoires Servier

Vernalis (R&D) Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-23

Filing date

2014-12-22

Publication date

2017-03-31

2014-12-22 Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier

2017-03-31 Publication of PL2886545T3 publication Critical patent/PL2886545T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hematology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL14199533T 2013-12-23 2014-12-22 Nowe pochodne tienopirymidyn, sposób ich wytwarzania, oraz zawierające je kompozycje farmaceutyczne PL2886545T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1363500A FR3015483B1 (fr)	2013-12-23	2013-12-23	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
PL2886545T3 true PL2886545T3 (pl)	2017-03-31

Family

ID=50829005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14199533T PL2886545T3 (pl)	2013-12-23	2014-12-22	Nowe pochodne tienopirymidyn, sposób ich wytwarzania, oraz zawierające je kompozycje farmaceutyczne

Country Status (48)

Country	Link
US (3)	US9670227B2 (pl)
EP (1)	EP2886545B1 (pl)
JP (1)	JP5922215B2 (pl)
KR (1)	KR101636401B1 (pl)
CN (1)	CN104725397B (pl)
AP (1)	AP2014008127A0 (pl)
AR (1)	AR098906A1 (pl)
AU (1)	AU2014274644B2 (pl)
BR (1)	BR102014032336B1 (pl)
CA (1)	CA2875226C (pl)
CL (1)	CL2014003444A1 (pl)
CO (1)	CO7210068A1 (pl)
CR (1)	CR20140569A (pl)
CU (1)	CU24309B1 (pl)
CY (1)	CY1118058T1 (pl)
DK (1)	DK2886545T3 (pl)
DO (1)	DOP2014000282A (pl)
EA (1)	EA029601B1 (pl)
ES (1)	ES2594377T3 (pl)
FR (1)	FR3015483B1 (pl)
GE (1)	GEP201706619B (pl)
GT (1)	GT201400297A (pl)
HK (2)	HK1209750A1 (pl)
HR (1)	HRP20161203T8 (pl)
HU (1)	HUE029654T2 (pl)
IL (1)	IL236143A (pl)
JO (1)	JO3193B1 (pl)
LT (1)	LT2886545T (pl)
MD (1)	MD4516C1 (pl)
ME (1)	ME02521B (pl)
MX (1)	MX351581B (pl)
MY (1)	MY185221A (pl)
NI (1)	NI201400150A (pl)
PE (1)	PE20151064A1 (pl)
PH (1)	PH12014000375B1 (pl)
PL (1)	PL2886545T3 (pl)
PT (1)	PT2886545T (pl)
RS (1)	RS55213B1 (pl)
RU (1)	RU2605403C2 (pl)
SA (1)	SA114360144B1 (pl)
SG (1)	SG10201408563UA (pl)
SI (1)	SI2886545T1 (pl)
TN (1)	TN2014000516A1 (pl)
TW (1)	TWI508969B (pl)
UA (1)	UA120341C2 (pl)
UY (1)	UY35915A (pl)
WO (1)	WO2015097123A1 (pl)
ZA (1)	ZA201409365B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3212202B1 (en)	2014-10-29	2020-05-06	The Walter and Eliza Hall Institute of Medical Research	Mcl-1 inhibitors for use in treating diseases caused by pathological neovascularisation
US20180179210A1 (en) *	2015-05-27	2018-06-28	Pharmascience Inc.	Inhibitors of the TEC Kinase Enzyme Family
FR3037957B1 (fr)	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) *	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3455218A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4491236A3 (en)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
EP3454862B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
EP3455219A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
UY37342A (es)	2016-07-22	2018-01-31	Servier Lab	Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
US20190240225A1 (en) *	2016-07-22	2019-08-08	Les Laboratoires Servier	Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX2019004941A (es) *	2016-10-28	2019-06-24	Servier Lab	Formulacion liposomal.
EP3567043B1 (en) *	2017-01-05	2023-12-06	Henan Genuine Biotech Co., Ltd.	2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
RU2763544C2 (ru) *	2017-01-06	2021-12-30	Ле Лаборатуар Сервье	Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
UY37560A (es) *	2017-01-06	2018-07-31	Servier Lab	Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EA039621B1 (ru) *	2017-06-09	2022-02-17	Ле Лаборатуар Сервье	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
UA126920C2 (uk) *	2017-06-22	2023-02-22	Ле Лаборатуар Сервьє	Комбінація інгібітору mcl-1 і стандартного лікарського препарату для лікування гематологічних злоякісних новоутворень, її застосування та фармацевтичні композиції, що її містять
GB201712282D0 (en)	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
EP3668504A4 (en) *	2017-08-15	2021-05-05	AbbVie Inc.	MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
US20200239494A1 (en) *	2017-08-15	2020-07-30	Abbvie Inc.	Macrocyclic mcl-1 inhibitors and methods of use
TW201920194A (zh) *	2017-08-15	2019-06-01	美商艾伯維有限公司	大環ｍｃｌ-１抑制劑及使用方法
CN107573360B (zh) *	2017-10-27	2019-08-09	都创(上海)医药科技有限公司	一种多靶点小分子化合物s63845的制备方法
WO2019101144A1 (zh) *	2017-11-23	2019-05-31	北京赛林泰医药技术有限公司	Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) *	2017-12-21	2019-09-20	河南真实生物科技有限公司	噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) *	2018-09-29	2022-04-12	江苏恒瑞医药股份有限公司	嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) *	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) *	2018-11-14	2024-07-21	法商施維雅藥廠	Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN111187277B (zh) *	2018-11-14	2022-04-12	江苏恒瑞医药股份有限公司	噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202039511A (zh)	2018-12-06	2020-11-01	法商施維雅藥廠	Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物
EP3897631A4 (en)	2018-12-20	2022-11-23	C4 Therapeutics, Inc.	TARGETED PROTEIN DEGRADATION
JOP20210289A1 (ar) *	2019-05-20	2023-01-30	Servier Lab	مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
WO2020254299A1 (en)	2019-06-17	2020-12-24	Les Laboratoires Servier	Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
AR119493A1 (es)	2019-07-29	2021-12-22	Servier Lab	Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
AR119494A1 (es)	2019-07-29	2021-12-22	Servier Lab	DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
JP2022551083A (ja) *	2019-10-03	2022-12-07	カリフォルニアインスティチュートオブテクノロジー	Ｍｃｌ１インヒビター及びその使用
CN113024578A (zh) *	2019-12-09	2021-06-25	首药控股(北京)有限公司	一种mcl1选择性抑制剂的多晶型物及其制备方法
CN113024577B (zh) *	2019-12-09	2023-06-30	首药控股(北京)股份有限公司	一种抗凋亡蛋白选择性抑制剂的制备方法
WO2022090443A1 (en)	2020-10-30	2022-05-05	Les Laboratoires Servier	Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CN117136076A (zh)	2020-11-24	2023-11-28	诺华股份有限公司	Mcl-1抑制剂抗体药物缀合物和使用方法
KR20230143605A (ko)	2020-11-24	2023-10-12	노파르티스 아게	Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
UY39609A (es)	2021-01-12	2022-08-31	Servier Lab	Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
KR20230170644A (ko)	2021-02-02	2023-12-19	르 라보레또레 쎄르비에르	선택적 bcl-xl protac 화합물 및 사용 방법
WO2022216946A1 (en) *	2021-04-07	2022-10-13	California Institute Of Technology	Mcl1 inhibitors and uses thereof
WO2022255888A1 (en) *	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
CA3222269A1 (en)	2021-06-11	2022-12-15	Gilead Sciences, Inc.	Combination mcl-1 inhibitors with anti-cancer agents
KR20240019330A (ko)	2021-06-11	2024-02-14	길리애드 사이언시즈, 인코포레이티드	Mcl-1 저해제와 항체 약물 접합체의 조합
KR20250027285A (ko)	2022-05-20	2025-02-25	노파르티스 아게	항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법
WO2023225320A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4525926A1 (en)	2022-05-20	2025-03-26	Novartis AG	Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2023302094A1 (en)	2022-07-08	2025-01-23	Les Laboratoires Servier	New spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4008726A1 (de) *	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
MXPA05013549A (es) *	2003-06-11	2006-04-05	Xention Discovery Ltd	Derivados de tienopirimidina como inhibidores del canal de potasio.
US20050165029A1 (en)	2004-01-13	2005-07-28	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20050288906A1 (en)	2004-06-29	2005-12-29	Drennen James K Iii	Spectroscopic pharmacy verification and inspection system
US7776867B2 (en)	2004-06-29	2010-08-17	Amgen Inc.	Furanopyrimidines
BRPI0513405A (pt) *	2004-07-16	2008-05-06	Sunesis Pharmaceuticals Inc	tienopirimidinas úteis como inibidores de aurora quinase
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
US7576080B2 (en) *	2004-12-23	2009-08-18	Memory Pharmaceuticals Corporation	Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP2078721B1 (en) *	2005-10-21	2014-01-22	Dow AgroSciences LLC	Thieno-pyrimidine compounds having fungicidal activity
CN101675053B (zh) *	2006-12-07	2014-03-12	健泰科生物技术公司	磷酸肌醇3-激酶抑制剂化合物及使用方法
DE102007027800A1 (de)	2007-06-16	2008-12-18	Bayer Healthcare Ag	Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
KR20100083170A (ko) *	2007-10-16	2010-07-21	와이어쓰 엘엘씨	티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 ｍＴＯＲ 키나제 및 ＰＩ3 키나제 억제제로서의 용도
TWI385174B (zh)	2008-11-10	2013-02-11	Nat Health Research Institutes	作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
NZ605988A (en) *	2010-06-23	2014-11-28	Hanmi Science Co Ltd	Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012044993A1 (en) *	2010-09-30	2012-04-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) *	2010-11-03	2014-06-04	中国科学院上海药物研究所	一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) *	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) *	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2013
- 2013-12-23 FR FR1363500A patent/FR3015483B1/fr not_active Expired - Fee Related
2014
- 2014-12-08 JO JOP/2014/0353A patent/JO3193B1/ar active
- 2014-12-09 IL IL236143A patent/IL236143A/en active IP Right Grant
- 2014-12-10 PH PH12014000375A patent/PH12014000375B1/en unknown
- 2014-12-10 CR CR20140569A patent/CR20140569A/es unknown
- 2014-12-11 TN TN2014000516A patent/TN2014000516A1/fr unknown
- 2014-12-11 CA CA2875226A patent/CA2875226C/en active Active
- 2014-12-12 AU AU2014274644A patent/AU2014274644B2/en active Active
- 2014-12-12 AP AP2014008127A patent/AP2014008127A0/xx unknown
- 2014-12-15 PE PE2014002444A patent/PE20151064A1/es active IP Right Grant
- 2014-12-15 DO DO2014000282A patent/DOP2014000282A/es unknown
- 2014-12-17 CU CUP2014000143A patent/CU24309B1/xx unknown
- 2014-12-18 CL CL2014003444A patent/CL2014003444A1/es unknown
- 2014-12-18 MY MYPI2014703853A patent/MY185221A/en unknown
- 2014-12-18 MX MX2014015854A patent/MX351581B/es active IP Right Grant
- 2014-12-18 ZA ZA2014/09365A patent/ZA201409365B/en unknown
- 2014-12-19 UA UAA201413661A patent/UA120341C2/uk unknown
- 2014-12-19 NI NI201400150A patent/NI201400150A/es unknown
- 2014-12-19 GE GEAP201413667A patent/GEP201706619B/en unknown
- 2014-12-19 CN CN201410800069.2A patent/CN104725397B/zh active Active
- 2014-12-19 US US14/576,683 patent/US9670227B2/en active Active
- 2014-12-19 JP JP2014257658A patent/JP5922215B2/ja active Active
- 2014-12-22 PT PT141995332T patent/PT2886545T/pt unknown
- 2014-12-22 MD MDA20140137A patent/MD4516C1/ro active IP Right Grant
- 2014-12-22 DK DK14199533.2T patent/DK2886545T3/en active
- 2014-12-22 EP EP14199533.2A patent/EP2886545B1/en active Active
- 2014-12-22 WO PCT/EP2014/078947 patent/WO2015097123A1/en active Application Filing
- 2014-12-22 SI SI201430061A patent/SI2886545T1/sl unknown
- 2014-12-22 GT GT201400297A patent/GT201400297A/es unknown
- 2014-12-22 EA EA201401292A patent/EA029601B1/ru unknown
- 2014-12-22 TW TW103144845A patent/TWI508969B/zh active
- 2014-12-22 HU HUE14199533A patent/HUE029654T2/en unknown
- 2014-12-22 SA SA114360144A patent/SA114360144B1/ar unknown
- 2014-12-22 ES ES14199533.2T patent/ES2594377T3/es active Active
- 2014-12-22 PL PL14199533T patent/PL2886545T3/pl unknown
- 2014-12-22 LT LTEP14199533.2T patent/LT2886545T/lt unknown
- 2014-12-22 BR BR102014032336-8A patent/BR102014032336B1/pt active IP Right Grant
- 2014-12-22 UY UY0001035915A patent/UY35915A/es active IP Right Grant
- 2014-12-22 AR ARP140104847A patent/AR098906A1/es active IP Right Grant
- 2014-12-22 SG SG10201408563UA patent/SG10201408563UA/en unknown
- 2014-12-22 RU RU2014151850/04A patent/RU2605403C2/ru active
- 2014-12-22 ME MEP-2016-207A patent/ME02521B/me unknown
- 2014-12-22 RS RS20160802A patent/RS55213B1/sr unknown
- 2014-12-23 KR KR1020140187349A patent/KR101636401B1/ko active Active
- 2014-12-23 CO CO14282098A patent/CO7210068A1/es unknown
2015
- 2015-10-28 HK HK15110667.4A patent/HK1209750A1/xx unknown
- 2015-12-16 HK HK15112389.7A patent/HK1211583A1/xx unknown
2016
- 2016-09-20 HR HRP20161203TT patent/HRP20161203T8/hr unknown
- 2016-09-22 CY CY20161100949T patent/CY1118058T1/el unknown
2017
- 2017-04-20 US US15/492,306 patent/US10278972B2/en active Active
2019
- 2019-03-08 US US16/296,766 patent/US20190201404A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2015097123A1 (en)	2015-07-02
IL236143A (en)	2017-02-28
KR101636401B1 (ko)	2016-07-05
CL2014003444A1 (es)	2015-10-23
US20170216293A1 (en)	2017-08-03
DOP2014000282A (es)	2016-06-30
EA201401292A3 (ru)	2015-08-31
CU20140143A7 (es)	2016-07-29
AR098906A1 (es)	2016-06-22
JP5922215B2 (ja)	2016-05-24
PT2886545T (pt)	2016-08-25
EP2886545A1 (en)	2015-06-24
US20190201404A1 (en)	2019-07-04
RU2014151850A (ru)	2016-07-20
CA2875226C (en)	2018-03-13
RS55213B1 (sr)	2017-02-28
AU2014274644A1 (en)	2015-07-09
ME02521B (me)	2017-02-20
RU2605403C2 (ru)	2016-12-20
PH12014000375A1 (en)	2016-06-13
US20150175623A1 (en)	2015-06-25
MD20140137A2 (ro)	2015-06-30
ZA201409365B (en)	2021-07-28
SI2886545T1 (sl)	2016-10-28
NZ702851A (en)	2016-05-27
HK1209750A1 (en)	2016-04-08
MD4516B1 (ro)	2017-09-30
US9670227B2 (en)	2017-06-06
KR20150073874A (ko)	2015-07-01
HUE029654T2 (en)	2017-02-28
UY35915A (es)	2015-07-31
LT2886545T (lt)	2016-09-26
SG10201408563UA (en)	2015-07-30
CO7210068A1 (es)	2015-03-09
HRP20161203T8 (hr)	2016-12-30
AU2014274644B2 (en)	2019-11-14
TW201529583A (zh)	2015-08-01
CU24309B1 (es)	2018-01-10
NI201400150A (es)	2015-06-05
BR102014032336B1 (pt)	2020-10-20
MX2014015854A (es)	2015-07-22
SA114360144B1 (ar)	2015-10-08
US10278972B2 (en)	2019-05-07
CN104725397A (zh)	2015-06-24
JO3193B1 (ar)	2018-03-08
TWI508969B (zh)	2015-11-21
CR20140569A (es)	2016-07-01
CA2875226A1 (en)	2015-06-23
UA120341C2 (uk)	2019-11-25
DK2886545T3 (en)	2016-09-19
HK1211583A1 (en)	2016-05-27
AP2014008127A0 (en)	2014-12-31
GEP201706619B (en)	2017-02-10
BR102014032336A2 (pt)	2016-06-07
MY185221A (en)	2021-04-30
MX351581B (es)	2017-10-20
EA029601B1 (ru)	2018-04-30
ES2594377T3 (es)	2016-12-19
FR3015483A1 (fr)	2015-06-26
EP2886545B1 (en)	2016-06-29
GT201400297A (es)	2017-08-24
TN2014000516A1 (en)	2016-03-30
CN104725397B (zh)	2017-11-28
EA201401292A2 (ru)	2015-06-30
JP2015129120A (ja)	2015-07-16
PE20151064A1 (es)	2015-08-08
FR3015483B1 (fr)	2016-01-01
HRP20161203T1 (hr)	2016-11-04
MD4516C1 (ro)	2018-04-30
PH12014000375B1 (en)	2017-10-11
CY1118058T1 (el)	2017-06-28

Publication	Publication Date	Title
HRP20161203T8 (hr)	2016-12-30	Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
HK1254657A1 (zh)	2019-07-26	新的羥基酯衍生物、其製備方法以及含有它們的藥物組合物
HK1203506A1 (en)	2015-10-30	New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
HK1204623A1 (en)	2015-11-27	New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
IL243742B (en)	2019-06-30	New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them
IL246406A0 (en)	2016-08-31	History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
HUP1300647A2 (hu)	2015-05-28	Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
IL239873A0 (en)	2015-08-31	The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL243012A0 (en)	2016-02-01	History of hydroxy-ethylene, their preparation and pharmaceutical preparations containing them
EP2925342A4 (en)	2016-07-06	NOVEL LANTIBIOTIC DERIVATIVES AND PREPARATION METHOD THEREOF